Sildenafil + DapoxetineThird Party Manufacturing in India

Sildenafil + Dapoxetine combines a phosphodiesterase-5 inhibitor with a selective serotonin reuptake inhibitor in a single tablet to address both erectile function and ejaculatory control in men with concurrent erectile dysfunction and premature ejaculation.

Sildenafil is a potent and selective inhibitor of phosphodiesterase-5 (PDE5), the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in the corpus cavernosum smooth muscle. Upon sexual stimulation, nitric oxide released from endothelial cells diffuses into adjacent smooth muscle cells and stimulates guanylate cyclase to produce cGMP. By preventing PDE5-mediated cGMP breakdown, sildenafil allows cGMP accumulation, which activates protein kinase G and triggers a signalling cascade that reduces intracellular calcium levels. This results in relaxation of the corpus cavernosum and penile artery smooth muscle, increasing blood inflow and producing a sustained erection sufficient for satisfactory sexual intercourse. The selectivity for PDE5 over other phosphodiesterase isoenzymes ensures that the vasodilatory effect is largely confined to the penile vasculature.

Dapoxetine is a short-acting SSRI that inhibits the serotonin reuptake transporter, increasing serotonin availability at the synaptic cleft in the central nervous system. This enhances serotonergic neurotransmission, which raises the ejaculatory threshold and delays the onset of ejaculation. Unlike conventional daily-dose SSRIs, dapoxetine is designed for on-demand use, with rapid absorption reaching peak plasma concentration in approximately one hour and a short elimination half-life that minimises accumulation and side effects. The combination provides dual control — haemodynamic for erection quality and serotonergic for ejaculatory latency.

Therapeutic Uses

Sildenafil + Dapoxetine is indicated for the treatment of:

• Concurrent Erectile Dysfunction and Premature Ejaculation: The primary indication for this combination. Clinical studies have shown that a significant proportion of men with erectile dysfunction also experience premature ejaculation. The fixed-dose combination addresses both conditions in a single tablet, eliminating the need for multiple medications and improving treatment adherence.
• Lifelong Premature Ejaculation with Secondary Erectile Difficulties: Men who have always experienced rapid ejaculation often develop performance anxiety that impairs erectile function. This combination breaks the cycle by simultaneously improving both parameters.
• Acquired Premature Ejaculation with Erectile Dysfunction: In men where erectile dysfunction developed first, leading to rushed intercourse and subsequent conditioned premature ejaculation, the combination restores normal sexual function.
• On-Demand Treatment: Unlike daily-dose therapies, dapoxetine is taken one to three hours before anticipated sexual activity, while sildenafil is taken approximately one hour before. The pharmacokinetic profiles of both drugs are well matched for concurrent on-demand use.

Why Manufacturers Choose Sildenafil + Dapoxetine

This combination represents one of the fastest-growing therapeutic segments in the Indian pharmaceutical market, driven by increasing awareness and destigmatisation of men's sexual health issues. India is the world's largest manufacturer of both sildenafil and dapoxetine APIs, offering manufacturers a significant cost advantage in raw material procurement. The combination is highly popular in PCD franchise models because of strong brand loyalty, high prescription volumes, and substantial margin opportunities. Manufacturers typically offer this combination in two strengths — 50mg+60mg and 100mg+30mg — to provide dosing flexibility. Export demand from Asia, Africa, and Latin America is exceptionally strong, with many buyers specifically sourcing WHO-GMP certified products from Indian manufacturers.

This makes Sildenafil + Dapoxetine one of the most commercially attractive combination products for third party manufacturing in India, with consistently growing demand across both domestic franchise and international export channels.